A dual-purpose biotech built on clinical resilience — reliable pharmaceutical supply for the NHS, with an exciting upcoming research and development pipeline.
Revenue from pharmaceutical supply funds the science. The science builds the company that lasts.
A direct pharmaceutical supply operation providing MHRA-approved medicines to NHS trusts. Where shortages create clinical risk, we provide reliable, compliant supply — and generate the revenues that fund our R&D pipeline.
Our lead therapeutic candidate targets pathological fibrosis using a novel enzymatic mechanism. At concept stage, Fibrin Eater I represents our long-term ambition — a curative treatment where none currently exists.
A two-year programme running both arms in parallel — commercial traction and scientific progress, sequenced with intention.
EternaForge Bio operates within and in active support of the NHS ecosystem, aligned with national healthcare policy and industry standards.
Whether you're an NHS procurement team, a potential scientific collaborator, or an investor interested in what we're building — reach out directly.